Pfizer's Inflectra: Report on Research and Development Program

This report provides a comprehensive overview of Pfizer's Inflectra, a biosimilar medicine. The report highlights the research and development processes involved, including its development for treating ulcerative colitis and its approval by the USFDA. The report mentions the medicine's effectiveness and its potential benefits for patients. It also discusses Pfizer's commitment to expanding its business and its focus on both generic and innovative medicines. The report references the company's website as a source for further information.

COMMUNICATION

TABLE OF CONTENTS
Introduction to products...................................................................................................................3

Introduction to products
I am Samuel from Pfizer and working as medical representative from last five years. Our
company is interested in building partnership with your firm to carry out research and
development project in respect to innovation of our medicine Inflectra. Today, I am here to give
you detail presentation on our company and mentioned medicine. Currently, Pfizer is the one of
the largest pharmaceutical firm in USA. Currently, firm is working on varied project under
which multiple products research and development programs are on progress. Number of
products or drugs are on pipeline and it is expected that within stipulated duration filling of drug
will be done at USFDA and patent will be obtained. Currently, I am talking about the newly
launched bio similar medicine which is Inflectra. Mentioned medicine is second bio similar drug
in the USA. It have been passed by the USFDA for release in the market. Mentioned disease is
used for the treatment of people that are suffered from pediatric disease. This treatment is
effective for those patients that are highly or moderately suffered from the mentioned disease.
Those patients in case of which there is active ulcerative colitis this medicine is very successful
as identified in our research. This medicine testing is done on number of people and it is
identified that it proved effective in case most of sample units (Pfizer, 2017). Thus, mentioned
product is recommended to the customers that are severely suffered from relevant disease. Pfizer
is fully committed towards expansion and diversification of its business. Under this research and
development team is focused both on generic and innovative medicines. Those whose license
will expired in upcoming time period, in respect to same generic medicines are developed which
will lead to plunge in the revenue in different verticals.

REFERENCES
Books and journals
Pfizer, 2017. [Online]. Available through :< http://www.pfizer.com/>. [Accessed on 5th June
2017].